Phase 3 Trial Evaluating Add-on Tecentriq for Advanced Ovarian Cancer Is Recruiting Participants

Phase 3 Trial Evaluating Add-on Tecentriq for Advanced Ovarian Cancer Is Recruiting Participants
A new Phase 3 trial will evaluate the potential of Tecentriq (atezolizumab) as an add-on therapy to Avastin (bevacizumab) plus chemotherapy in advanced ovarian cancer patients. The trial, called ATALANTE (NCT02891824), was designed to test Tecentriq versus placebo as a maintenance therapy for patients who first responded to platinum-based chemotherapy but relapsed after six months or

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *